Last Tuesday, over a $38 adaptogenic matcha in Hayes Valley, a two-time startup dropout leaned across the table and told me he was about to disrupt the pancreas.
He is not alone. This week, the FDA is expected to decide whether to loosen or tighten the regulatory framework around the production of peptides—the class of molecules that includes blockbuster weight-loss drugs like Ozempic and Wegovy. If the agency backs off, it will trigger an immediate, massive expansion of compounded alternatives.
The legacy press, predictably, is framing this as a public health hazard. They are calling it a "cash grab" by opportunistic telehealth platforms who want to pump out unverified GLP-1 agonists to anyone with a credit card and an internet connection. They are demanding oversight.
I have a different perspective. If you look at this from first principles, what is a peptide, really? It is just a short chain of amino acids. It is biological code. Right now, legacy pharmaceutical monopolies like Eli Lilly and Novo Nordisk are treating this code like proprietary, closed-source software, charging $1,000 a month for a licensed seat.
Enter the telehealth founders. Companies like Hims & Hers and Ro have already begun exploiting the FDA’s shortage loopholes to offer compounded versions of these drugs at a fraction of the cost.
The genius of the compounding loophole is that it treats pharmaceutical patents as mere suggestions. Because the FDA declared a national shortage of semaglutide, telehealth platforms are legally permitted to partner with pharmacies to mix their own bootleg versions. It is regulatory arbitrage at its finest.
But the next wave of startups isn't just looking at compounding pharmacies; they are looking at raw peptide synthesis. They are realizing that the regulatory moat is artificial.
I sat in on a pitch meeting on Sand Hill Road last month for a startup called Voxel Health. Their pitch was elegant: abstract away the doctor, abstract away the pharmacy, and connect the consumer directly with wholesale peptide synthesis labs via a slick iOS interface.
Right now, getting a prescription for a branded GLP-1 requires seeing an actual physician, undergoing bloodwork, and discussing your medical history. Telehealth platforms have beautifully optimized this funnel. You fill out a three-minute web form, upload a selfie, and an algorithm determines you are legally qualified to receive a vial of custom-mixed powder in the mail. It is a frictionless user journey.
The venture capitalists in the room were salivating. Why? Because injecting a user with an appetite suppressant every week is the ultimate subscription model. It is physical SaaS. Your body literally churns if you cancel your membership.
Critics argue that skipping clinical trials and mass-producing injectable hormones without FDA oversight could lead to catastrophic health outcomes. They point out that some of these raw compounds are being mixed in facilities that also manufacture industrial solvents.
This is the fundamental disconnect between regulators and builders. The FDA views a contaminated batch as a tragedy. Silicon Valley views it as an A/B test.
We aren't selling unverified chemicals; we're offering high-agency individuals early access to beta molecules.
This is the mindset of a winner. Larrabee understands that a little bit of nausea, or perhaps temporary localized tissue necrosis, is just a breaking change in the user’s endocrine system. It is the body’s way of saying it needs to adapt to the new API.
If we restrict peptide production to highly regulated, sterilized laboratories overseen by cautious scientists, we are stifling innovation. We are telling the 24-year-old product manager who wants to ship a custom muscle-growth hormone to his loyal subscribers that his vision does not matter.
Yes, there will be volatility. Some direct-to-consumer platforms might accidentally distribute a batch of tirzepatide that causes severe heart palpitations. But we have to ask ourselves: are a few thousand hospitalizations really too high a price to pay for disrupting the legacy pharmaceutical cartel?
The people complaining about the lack of long-term safety data are the same people who complained that Uber didn't have taxi medallions. They are anchored to the past, terrified of a future where anyone can alter their gastric emptying rate with a promo code.
When the FDA makes its ruling this week, I hope they recognize that the future of medicine isn't going to be built in a sterile clinic. It is going to be built in a collaborative document, funded by a seed round, and shipped directly to your doorstep in minimalist, millennial-pink packaging.
We should not be punishing the founders who are brave enough to monetize our insecurities via lightly regulated injectables. We should be thanking them for stepping into the arena.
